[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"MiNK Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100637440","phase-2-a-clinical-trial-to-evaluate-agent-797-plus-standard-of-care-in-participants-with-severe-pneumonia-with-moderate-to-severe-acute-hypoxemic-respiratory-failure-100637440",false,"NCT07615010","A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure","Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria","Key Inclusion Criteria:\n\n* Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based on clinical suspicion\n* Acute hypoxemic respiratory failure (AHRF)\n* Evidence of moderate to severe acute respiratory distress syndrome (ARDS) based on Global ARDS criteria\n* Onset of severe pneumonia with AHRF ≤7 days prior to informed consent\n\nKey Exclusion Criteria:\n\n* More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent\n* Pregnancy or breastfeeding\n* History of cytokine release syndrome, as documented in the medical record or reported by the participant, legally authorized representative, or close relative\n* Current participation in another interventional clinical trial, or receipt of an investigational medicinal product within 30 days prior to screening, unless reviewed and approved in writing by the medical monitor\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},90,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).",[26],"Pneumonia",[28,29,30],"Acute Hypoxemic Respiratory Failure","AHRF","agenT-797","RECRUITING","2026-06-25",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":35},"2026-05-26",{"date":39,"type":20},"2027-08",{"name":41,"class":42},"MiNK Therapeutics","INDUSTRY",4,""]